ALS Treatment gets U.S. FDA Approval
The Food and Drug Administration on Friday cleared a treatment for fatal neurological disorder ALS, marking the first such U.S. regulatory approval in more than two decades. The drug, known chemically as edaravone, is already sold by Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corp in Japan and South Korea. In the United States, the only other approved ALS medicine, generic riluzole, modestly slows the progression of the disease in some people. After six months of treatment with edaravone on top of standard-of-care, data showed the intravenous drug reduced the rate of functional decline in patients by about a third, Dr Jean Hubble, VP of medical affairs, at MTPC.
This video was produced by YT Wochit News using http://wochit.com